Sulzer AG · SIX:SUN
Sulzer — Merger or Acquisition (June 2021)
17 slides from Sulzer's merger presentation, June 2021
Slide 1: Spin-off of APS as medmix: Roadshow presentation
Spin-off of APS as Roadshow presentation June 2021
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, containing risks and uncertainties. These forward- looking statements are su
Slide 3: Today's presenters
Today’s presenters Greg Poux-Guillaume Jill Lee Girts Cimermans Chairman, medmix Director, medmix CEO, medmix ▪ CEO of Sulzer since 2015 ▪ CFO of Sulzer since 2018 ▪ Former CEO, Hoya Vision Care ▪ Former CEO of GE Grid Solutions, EVP Alstom ▪ Former SVP/CFO ABB, Siemens ▪ Former Pentax Medical presi
Slide 4: Sulzer: technology incubator since 1834
Sulzer: technology incubator since 1834 Pumps since 1834 Heating and Air Condition 1841 – 2001 Thermal energy systems 1841 – 1997 Steam engines 1854 – 1952 Shipbuilding 1867 – 1934 Rock drilling machine / Tunneling 1876 – 1905 Refrigeration systems 1877 – 2001 Reciprocating compressors 1878 – 2002 D
Slide 5: Transaction summary
Transaction summary ▪ Sulzer has built APS into a leader in high-precision delivery devices, now well positioned to succeed and grow as an independent entity ▪ Sulzer has also significantly diversified its core portfolio, shifting away from energy towards water, chemicals and biopolymers, and a uniq
Slide 6: Transaction rationale
Transaction rationale Two focused leaders for attractive end-markets Flow control specialist for water, chemical, industry and energy Innovative, high-precision delivery devices • A global leader in industrial flow control • Leading positions in dental, pharma, adhesives and beauty • Continuous shif
Slide 7: medmix snapshot
snapshot Innovative, high-precision delivery devices serving attractive markets Healthcare Consumer and Industrial Drug Dental Surgery Industry Beauty delivery Gold standard in Award winning, Pioneer in bone Leader in industrial Leading dental mixing proprietary injection cement mixing mixing and di
Slide 8: medmix product success stories
product success stories Drug Dental Surgery Industry Beauty Delivery 3 2 1 MedmixTM Prefilled Mixpac™ T-Mixer™ evolution Axis-D™Platform Bi-material mascara brushes Double Syringe System B&F system ▪ Internally developed ▪ Disposable variable dose ▪ Leading double syringe ▪ Leading dispensing ▪ Inte
Slide 9: medmix financial highlights and mid-term targets
financial highlights Attractive financial profile with substantial revenue growth and highly resilient margins 2021E sales CHF 450m ~25% adj. EBITDA margin Mid-term targets High single digit Healthcare share in sales EBITDA margin target sales growth >50% ~30% Expected leverage post capital increase
Slide 10: Vision for medmix
Vision for Diversified exposure to growing end-markets, with healthcare segments growing fastest ✓ • Attractive and resilient B2B niche markets Niche leader • Exciting underlying macro growth trends • Fragmented competitive landscape ✓ • High entry barriers, e.g. regulation Highly • High IP protecti
Slide 11: Vision for Sulzer
Vision for Sulzer Accelerate repositioning towards sustainable applications and push aftermarket > 50% ✓ Capitalize on leadership in high-barrier-to-entry markets through Sulzer’s technology, service capabilities and proven digital advance ✓ Focus on sustainable sectors for mid-term growth, e.g. Wat
Slide 12: Financial guidance 2021
Financial guidance 2021 As of May 27, 2021, adjusted for FX, including acquisitions already closed Sales (CHF) Operational Profitability % ~3bn ~9% opEBITA margin ~25% adj. EBITDA margin ~450m (equivalent to ~19% opEBITA margin) 12
Slide 13: Leverage and capital increase considerations
Leverage and capital increase considerations Leverage ratio of ~1.4-1.6x for Sulzer and ~1-2x for medmix post Transaction Net debt1 (CHFbn) and leverage ratio (x) – illustrative as per H1 2021E Considerations Deleveraging of Sulzer * 2.1x ~2.0-2.2x ~1.4-1.6x ~1-2x ▪ Capital increase of CHF200-300m c
Slide 14: Highlights on credit profile post Transaction
Highlights on credit profile post Transaction Sulzer and medmix expected to substantially benefit from the split and concurrent capital increase (the "Transaction") Post Transaction, both Sulzer and medmix will have lower leverage levels compared to Sulzer Group today Capital increase of CHF200-300m
Slide 15: Indicative transaction timetable
Indicative transaction timetable 15-Jun-2021 2021 Capital Markets Day 22-Jul-2021 Publication of H1 2021 results Late Q3 2021 Extraordinary Shareholder Meeting H2 2021 Spin-off and capital increase / first trading day of medmix at SIX 15
Slide 16: Key takeaways
Key takeaways ▪ Split into two focused companies with different end-markets via a separate stock market listing of medmix ▪ While medmix will focus on healthcare and further develop its industrial and consumer markets, Sulzer will become a pure play industrial flow control company ▪ Transaction to l
Slide 17: Your Investor Relations contact
Your Investor Relations contact Christoph Ladner Head of Investor Relations Sulzer Management Ltd Phone: +41 52 262 30 22 Neuwiesenstrasse 15 Mobile: +41 79 326 69 70 8401 Winterthur E-mail: christoph.ladner@sulzer.com Switzerland www.sulzer.com